Daré Bioscience regains Nasdaq compliance but faces one-year Mandatory Panel Monitor

Dare Bioscience, Inc.

Received Nasdaq letter confirming compliance with stockholders' equity rule (Nasdaq 5550(b)(1)) on July 24, 2025.
Subject to Mandatory Panel Monitor for one year from July 24, 2025.
If non-compliance within year, delist determination with no right to submit compliance plan or cure period.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.